Compare Stocks: IPHA, ANNX, DSGN, and CLYM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANNX Annexon	$3.87 -7.4%	$4.96	$2.54 ▼ $7.18	$792.44M	1.21	2.83 million shs	2.42 million shs
CLYM Climb Bio	$12.52 -11.9%	$14.29	$1.54 ▼ $18.33	$816.17M	0.09	1.74 million shs	2.14 million shs
DSGN Design Therapeutics	$12.36 -6.1%	$13.82	$5.28 ▼ $17.25	$823.58M	1.66	770,108 shs	738,274 shs
IPHA Innate Pharma	$1.76 -2.2%	$1.98	$1.17 ▼ $2.71	$201.09M	0.34	43,408 shs	23,669 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANNX Annexon	-7.42%	-1.53%	-23.52%	-24.85%	+32.99%
CLYM Climb Bio	-11.89%	-11.27%	-23.66%	-1.11%	+456.44%
DSGN Design Therapeutics	-6.08%	-1.20%	-18.84%	-8.04%	+105.32%
IPHA Innate Pharma	-2.22%	-12.44%	-20.00%	-1.68%	-3.03%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANNX Annexon	$3.87 -7.4%	$4.96	$2.54 ▼ $7.18	$792.44M	1.21	2.83 million shs	2.42 million shs
CLYM Climb Bio	$12.52 -11.9%	$14.29	$1.54 ▼ $18.33	$816.17M	0.09	1.74 million shs	2.14 million shs
DSGN Design Therapeutics	$12.36 -6.1%	$13.82	$5.28 ▼ $17.25	$823.58M	1.66	770,108 shs	738,274 shs
IPHA Innate Pharma	$1.76 -2.2%	$1.98	$1.17 ▼ $2.71	$201.09M	0.34	43,408 shs	23,669 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANNX Annexon	-7.42%	-1.53%	-23.52%	-24.85%	+32.99%
CLYM Climb Bio	-11.89%	-11.27%	-23.66%	-1.11%	+456.44%
DSGN Design Therapeutics	-6.08%	-1.20%	-18.84%	-8.04%	+105.32%
IPHA Innate Pharma	-2.22%	-12.44%	-20.00%	-1.68%	-3.03%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANNX Annexon	2.40	Hold	$15.14	291.29% Upside
CLYM Climb Bio	3.00	Buy	$26.92	115.04% Upside
DSGN Design Therapeutics	2.88	Moderate Buy	$16.50	33.50% Upside
IPHA Innate Pharma	2.67	Moderate Buy	$6.67	278.79% Upside

Current Analyst Ratings Breakdown

Latest IPHA, ANNX, DSGN, and CLYM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/21/2026	IPHA Innate Pharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/17/2026	IPHA Innate Pharma	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$9.00
9/16/2026	CLYM Climb Bio	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/8/2026	CLYM Climb Bio	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$18.00 ➝ $25.00
9/8/2026	CLYM Climb Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$24.00 ➝ $30.00
9/7/2026	CLYM Climb Bio	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/4/2026	CLYM Climb Bio	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/4/2026	CLYM Climb Bio	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$26.00 ➝ $30.00
9/3/2026	CLYM Climb Bio	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Overweight	$40.00
9/3/2026	CLYM Climb Bio	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$21.00 ➝ $25.00
9/3/2026	CLYM Climb Bio	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$20.00 ➝ $32.00

(Data available from 9/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANNX Annexon	N/A	N/A	N/A	N/A	$1.42 per share	N/A
CLYM Climb Bio	N/A	N/A	N/A	N/A	$3.36 per share	N/A
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	$3.73 per share	N/A
IPHA Innate Pharma	$10.19M	19.30	N/A	N/A	($0.26) per share	-6.77

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANNX Annexon	-$206.69M	-$1.16	N/A	N/A	N/A	N/A	-106.15%	-79.82%	11/9/2026 (Estimated)
CLYM Climb Bio	-$59.85M	-$0.83	N/A	N/A	N/A	N/A	-31.79%	-30.79%	11/11/2026 (Estimated)
DSGN Design Therapeutics	-$69.79M	-$1.18	N/A	N/A	N/A	N/A	-34.03%	-32.05%	11/4/2026 (Estimated)
IPHA Innate Pharma	-$55.64M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest IPHA, ANNX, DSGN, and CLYM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	ANNX Annexon	-$0.2388	-$0.28	-$0.0412	-$0.28	$6.50 million	N/A
8/6/2026	Q2 2026	CLYM Climb Bio	-$0.2093	-$0.18	+$0.0293	-$0.18	N/A	N/A
8/3/2026	Q2 2026	DSGN Design Therapeutics	-$0.3443	-$0.32	+$0.0243	-$0.32	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANNX Annexon	N/A	N/A	N/A	N/A	N/A
CLYM Climb Bio	N/A	N/A	N/A	N/A	N/A
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	N/A
IPHA Innate Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANNX Annexon	N/A	5.53	5.53
CLYM Climb Bio	N/A	31.45	31.45
DSGN Design Therapeutics	N/A	18.86	18.86
IPHA Innate Pharma	N/A	0.60	1.27

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANNX Annexon	N/A
CLYM Climb Bio	69.76%
DSGN Design Therapeutics	56.64%
IPHA Innate Pharma	0.16%

Insider Ownership

Company	Insider Ownership
ANNX Annexon	10.31%
CLYM Climb Bio	2.60%
DSGN Design Therapeutics	17.10%
IPHA Innate Pharma	31.89%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANNX Annexon	92	189.58 million	170.03 million	Optionable
CLYM Climb Bio	29	57.44 million	55.94 million	N/A
DSGN Design Therapeutics	55	62.58 million	51.88 million	Optionable
IPHA Innate Pharma	163	111.72 million	76.09 million	Not Optionable

IPHA, ANNX, DSGN, and CLYM Headlines

Recent News About These Companies

Innate Pharma (IPHA) Upgraded to Buy: Here's What You Should Know

September 23 at 1:01 PM | zacks.com

HC Wainwright Boosts Earnings Estimates for Innate Pharma

September 23 at 8:12 AM | marketbeat.com

Innate Pharma (IPHA) Closes Sobi Deal. Can the New Funding Keep Drug Trials on Track?

September 23 at 1:05 AM | finance.yahoo.com

Analysts Offer Insights on Healthcare Companies: Innate Pharma (IPHA) and Alnylam Pharma (ALNY)

September 22 at 8:25 AM | theglobeandmail.com

Analysts Set Expectations for Innate Pharma FY2029 Earnings

September 22 at 7:27 AM | marketbeat.com

Innate Pharma (NASDAQ:IPHA) Earns "Buy" Rating from BTIG Research

September 19, 2026 | americanbankingnews.com

Innate Pharma (IPHA) Q2 2026 Earnings Call Transcript

September 18, 2026 | aol.comA

Innate Pharma S.A. (IPHA) Q2 2026 Earnings Call Transcript

September 17, 2026 | seekingalpha.com

Innate Pharma Reports H1 Loss Narrows; Advances Lacutamab And IPH4502

September 17, 2026 | rttnews.com

BTIG Research Reaffirms Buy Rating for Innate Pharma (NASDAQ:IPHA)

September 17, 2026 | marketbeat.com

Innate Pharma Q2 Earnings Call Highlights

September 17, 2026 | marketbeat.com

Innate Pharma Reports First Half 2026 Business Update and Financial Results

September 17, 2026 | streetinsider.com

Sobi and Innate announce partnership is now effective following completion of closing conditions

September 17, 2026 | finance.yahoo.com

Innate Pharma, Sobi Partnership Becomes Effective

September 17, 2026 | finance.yahoo.com

Innate and Sobi Announce Partnership Is Now Effective Following Completion of Closing Conditions

September 16, 2026 | finance.yahoo.com

Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Short Interest Update

September 13, 2026 | marketbeat.com

Innate Pharma to Host Conference Call and Webcast on September 17 for First Half 2026 Financial Results and Business Update

September 10, 2026 | finance.yahoo.com

Innate Pharma (IPHA) Projected to Post Quarterly Earnings on Thursday

September 10, 2026 | marketbeat.com

Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Receives Average Recommendation of "Moderate Buy" from Brokerages

September 5, 2026 | marketbeat.com

Innate Pharma participera à la H.C. Wainwright 28th annual global investment conference

September 3, 2026 | afp.comA

Innate Pharma S.A. (IPHA) Discusses EUR 30 Million Equity Raise, Strategic Partnership and Pipeline Advancement Transcript

August 14, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPHA, ANNX, DSGN, and CLYM Company Descriptions

Annexon NASDAQ:ANNX

$3.87 -0.31 (-7.42%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$3.86 -0.01 (-0.36%)

As of 04:05 AM Eastern

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Climb Bio NASDAQ:CLYM

$12.52 -1.69 (-11.89%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$12.38 -0.14 (-1.09%)

As of 05:39 AM Eastern

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.

Design Therapeutics NASDAQ:DSGN

$12.36 -0.80 (-6.08%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$12.40 +0.04 (+0.32%)

As of 05:24 AM Eastern

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Innate Pharma NASDAQ:IPHA

$1.76 -0.04 (-2.22%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$1.77 +0.01 (+0.62%)

As of 04:35 AM Eastern

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IPHA, ANNX, DSGN, and CLYM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IPHA, ANNX, DSGN, and CLYM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IPHA, ANNX, DSGN, and CLYM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPHA, ANNX, DSGN, and CLYM Company Descriptions

Annexon NASDAQ:ANNX

Climb Bio NASDAQ:CLYM

Design Therapeutics NASDAQ:DSGN

Innate Pharma NASDAQ:IPHA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IPHA, ANNX, DSGN, and CLYM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IPHA, ANNX, DSGN, and CLYM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IPHA, ANNX, DSGN, and CLYM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPHA, ANNX, DSGN, and CLYM Company Descriptions

Annexon NASDAQ:ANNX

Climb Bio NASDAQ:CLYM

Design Therapeutics NASDAQ:DSGN

Innate Pharma NASDAQ:IPHA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools